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Long-Term Endocrine Function in Hypercholesterolemic Patients Treated With 
Pravastatin, a New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor 
Adrian S. Dobs, P. Sankara Sarma, and David Schteingart 
Steroid hormone production within the gonads and adrenals requires a continuous supply of cholesterol derived from de novo 
synthesis within the gland and from uptake of circulating plasma lipoproteins. Steroid hormone secretion was prospectively 
studied over 24 months in 64 hypercholesterolemic subjects (group I, aged 52 + 1 years [mean f SEMI, 61% male) participating 
in a randomized double-blind clinical trial of pravastatin (20 to 60 mg daily), a new 3-hydroxy-3-methylglutaryl coenryme A 
(HMG-CoA) reductase inhibitor, compared with patients taking cholestyramine or other lipid-lowering drugs (group II). 
Attempts were made in both groups to maintain serum low-density lipoprotein cholesterol (LDL-C) levels between the 25th and 
50th percentile for age and gender. At 24 months, serum LDL-C level decreased by 42% + 3% in group I and 44% + 1% in group 
II (P c .OOl Y baseline, NS between groups). Basal secretion of cortisol, aldosterone, and dehydroepiandrostenedione sulfate 
(DHEA-S) was maintained throughout the study. However, the serum DHEA-S secretory response to Cortrosyn (Organon, West 
Orange, NJ) diminished in both treatment groups at 6 and 12 months (P < .05). In men, basal serum testosterone levels and the 
testosterone response to human chorionic gonadotropin (HCG) did not change. There was some diminution of sperm motility 
noted in both treatment groups at 6 and 12 months in the subset of men undergoing semen analysis (n = 14, P < .05). In 
conclusion, pravastatin had no significant effect on steroid metabolism. Changes noted in DHEA-S were not specific for 
pravastatin, suggesting that this impairment is related to lipid-lowering effects. 
c OMPLIANCE WITH the National Cholesterol Educa- tion Program Adult Treatment Guidelines’ will per- 
mit large segments of the population to be treated for 
hypercholesterolemia over extended periods of time. The 
3-hydroxy-3-methylglutaryl wenzyme A (HMG-CoA) reduc- 
tase inhibitors are a new class of lipid-lowering agents that 
offer an effective and relatively safe intervention for the 
treatment of hypercholesterolemia. An example of this 
class of drugs is lovastatin, which is found to produce 30% 
to 40% reductions in low-density lipoprotein cholesterol 
(LDL-C) levels.2-4 Pravastatin, another drug of this type 
with comparable lipid-lowering efficacy,5 is structurally 
similar, but its tissue specificity may vary.6,7 Few side effects 
have been reported with either lovastatin or pravastatin. 
phosphate, a lipid-carrier molecule required for glycosyla- 
tion of gonadotropins8 
The possibility that inhibition of cholesterol synthesis 
may interfere with adrenal cortical and gonadal function is 
a concern for patients treated with these drugs. Lipid- 
lowering agents may impair steroid hormone synthesis 
directly by decreasing the availability of circulating choles- 
terol for endocrine gland uptake (common to all hypolipid- 
emit drugs) or diminishing in situ cholesterol synthesis 
(specific for HMG-CoA reductase inhibitors), or indirectly 
in the case of the gonads by altering levels of dolichol 
In cultured human fetal adrenal cortical cells, the major- 
ity of cholesterol was obtained via the LDL receptor 
pathway.g Subjects with heterozygous familial hypercholes- 
terolemia have normal basal cortisol concentrations but 
attenuated cortisol responses to corticotropin administra- 
tion.‘O In the basal state, enhanced in situ cholesterol 
biosynthesis may compensate for defective uptake of LDL.‘] 
Studies in small groups of genetically mixed hypercholester- 
olemic patients treated with lovastatin demonstrated vari- 
able effects on adrenal steroid hormone secretion.12-I4 Peak 
cortisol secretion was blunted after corticotropin adminis- 
tration in 24 patients treated for 8 weeks with simvastatin.14 
Plasma aldosterone levels were within normal limits, but 
reduced after 9 months of simvastatin.15 
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Although in vitro basal and human chorionic gonadotro- 
pin (HCG)-stimulated testosterone production in rat Ley- 
dig cells was impaired with short-term lovastatin administra- 
tion,15 serum testosterone levels were maintained in a 
clinical trial using lovastatin. I6 Degeneration of seminifer- 
ous epithelium in the testes has been observed in dogs 
receiving lovastatin 20 mgikg per day.” Hyperlipidemic 
men maintained their serum levels of gonadotropins and 
semen analyses after 4 months of treatment with either 
neomycin or lovastatin.8 Recently in a study of porcine 
ovarian theta cells, lovastatin was noted to have an addi- 
tional inhibitory action at the level of the 17-hydroxylase:C- 
17,20-lyase complex, resulting in decreased androstenedi- 
one production. I7 The present study was undertaken to 
determine the effects of long-term use of pravastatin, a new 
HMG-CoA reductase inhibitor, on adrenal and gonadal 
function in men and women. 
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Subjects 
SUBJECTS AND METHODS 
Men and postmenopausal or surgically sterile women aged 21 to 
70 were selected; they were recruited from newspaper advertise- 
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ments and publicized screenings to measure serum cholesterol. 
Subjects qualified for randomization into active treatment if they 
had three consecutive fasting serum LDL-C levels greater than 
both 160 mg/dL and the 75th percentile for age and sexI after at 
least 6 weeks of dietary compliance. Serum triglyceride levels were 
lower than 250 mg/dL in all subjects. Patients were excluded if they 
had evidence of endocrine, renal, or hepatic disease, diabetes 
mrllitus (fasting blood glucose > 140 mg/dL), or unstable cardiac 
disease. 
Pravastatin was used in a double-blind placebo-controlled clini- 
cal trial at four centers within the United States (Fig 1). All 
subjects received a Step 1 American Heart Association lipid- 
lowering diet”’ for at least 6 weeks before randomization. The diet 
was maintained throughout the study,‘” and patients had regular 
follow-up visits with a dietitian to evaluate and reinforce dietary 
compliance. A 4-week placebo lead-in period was included before 
randomization during the diet phase. Patients were randomized to 
receive either pravastatin (group I) or other hypocholesterolemic 
drugs (group II: predominantly cholestyramine). During the first 6 
mctnt7s of the study. group I patients received pravastatin 40 mg 
daily plus placebo cholestyramine powder; group II patients 
recensed cholestyramine 16 g daily plus placebo tablets. Ten 
subjezts were taking only a placebo tablet for the first 4 months. 
These, patients were then rerandomized to an active treatment 
groul 
After 6 months, lipid-lowering medications could be adjusted in 
both groups to maintain serum LDL levels between the 25th and 
50th percentile for age and sex. i8 In group I, the placebo powder 
wax discontinued at 6 months and pravastatin could be increased 
up to 80 mg daily; after 1 year, cholestyramine could be added to 
the tr:atment regimen for group I subjects. In group II. the placebo 
tablet for pravastatin was continued throughout the study period; 
five patients in Group II were allowed to start niacin or probucol 
treatment. Thus, throughout the study, subjects were treated with 
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Fig 1. Study design. In the prerandomization phase, dietary inter- 
vention alone occurred between month -1.5 and 0. A placebo lead-in 
phase occurred in month -1. Patients were then randomized to a 
double-blind clinical trial in group I (pravastatin 40 mg daily) or group 
II (cholestyramine up to 16 g daily) for 6 months. In group I, after 6 
months pravastatin dosage could be increased to 80 mg daily and 
after 12 months cholestyramine could be added to maintain serum 
LDL-C levels between the 25th and 50th percentilel* for gender- and 
age-matched controls. In group II, chofestyramine dosage could be 
increased to 32 g daily after 6 months to maintain serum LDL-C levels 
at levels comparable to those in group I. Ten subjects were taking 
only a placebo tablet for the first 4 months and were then rerandom- 
ized to an active treatment group. Five patients in group II were 
allowed to start niacin or probucol treatment. Endocrine testing was 
performed 0,6,12,18, and 24 months after randomization. 
varying doses I I pravastatin or cholestyramine depending on their 
serum lipid co,:entrations. The study was approved by The Johns 
Hopkins Medic, Institutions Review Board: all patients gave 
informed consent. 
Endocrine Testing 
Hormone studies were performed at baseline and 6, 12. 18, and 
24 months after randomization. For evaluating adrenal cortical 
function, cortisol, aldosterone, and dehydroepiandrostenedione 
sulfate (DHEA-S) levels were measured before and 30, 60, and 90 
minutes after intravenous administration of 250 ug synthetic 
corticotropin (Cortrosyn, Organon, West Orange. NJ): basal corti- 
cotropin and renin levels were also measured. 
Gonadal function was evaluated by measuring basal levels of 
serum progesterone, prolactin, follicle-stimulating hormone (FSH). 
luteinizing hormone (LH), total and free testosterone. and estra- 
diol. In a subset of men, a semen analysis was obtained and serum 
testosterone level was measured 24 and 48 hours after intramuscu- 
lar injection of HCG 2.500 IU. All blood was obtained between the 
hours of 8:00 and 10:00 AM and immediately centrifuged; serum 
was shipped on dry ice to a central laboratory where all samples 
were assayed. One semen sample was obtained at each time point 
from participants from Johns Hopkins University and the Univer- 
sity of Michigan after a period of abstinence of 3 days. Significant 
illnesses during the previous 3 months were documented. Men 
were recruited into the study over a l-year period, thus permitting 
serum samples to be collected through all seasons. Semen analyses 
were performed within 2 hours of obtaining the sample by a 
dedicated technician for each site (with a second one available for 
vacations, etc.) in the following manner. Density was determined 
manually using a counting chamber, and percent motility was 
reported after a manual observation of 200 sperm. Criteria for 
normal sperm morphology were determined manually by the 
presence of a sheath. head. and a single tail. A nigrosin-eosinophil 
stain was performed to determine the viability of the sperm; the 
degree of dye uptake correlates with the percent normal morphol- 
ogy. 
Assays 
All hormone measurements were performed by radioimmunoas- 
say; all individual samples were assayed in the same assay. All 
steroid hormone levels (cortisol [sensitivity, 0.2 FgidL]. aldoste- 
rone [sensitivity, 16.0 pg/mL], DHEA-S [sensitivity. 2.1 ug/dL], 
progesterone [sensitivity, 0.05 ng/mL], estradiol [sensitivity, 8.0 
pg/mL]. and total and free testosterone [sensitivity, 110 pg/dL]) 
were measured by solid-phase radioimmunoassay (I-135 radioim- 
munoassay Coat-A-Count Kit method, Diagnostic Product Corp. 
Los Angeles, CA). Interassay and intraassay coefficients of varia- 
tion ranged from 5% to 8%. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol, and triglycerides (TG) were ana- 
lyzed using microenzymatic procedures on a Hitachi autoanalyzer 
model 705 (BMD, Indianapolis, IN) as previously described.r’ 
HDL-C was isolated using the modified Lipid Research Clinics 
procedure (heparin-2 mot/L manganese chloride).?’ LDL-<I level 
was calculated from the Friedewald formula.‘3 
Statistical Analysis 
Statistical analysis was performed using Statistical Analysis 
Systems (SAS Institute, Gary. NC) on a mainframe computer and 
CLINFO in The Johns Hopkins University School of Hygiene and 
Public Health. Data were analyzed using two approaches. In the 
first, all subjects were grouped as a whole without distinction for 
treatment assignment. In the second. patients were classified into 
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Table I. Baseline Characteristics of Subjects in Group I 
(pravastatin-treated) and Group II (other lipid-lowering agents) 
Total subjects (% male) 
Age (~1 
SEM 
















Group II Total 









the first year of the clinical trial; a subset of 10 patients 
continued for 24 months. There were no statistically signifi- 
cant differences in baseline age, gender distribution, or 
total serum cholesterol or LDL-C concentrations between 
the two groups at initiation of the study (Table 1). At 24 
months, LDL-C levels decreased by 42% + 3% in group I 
and 44% ? 1% in Group II (P < .OOl v baseline, NS 
between groups). Drug dosages were altered to maintain 
serum LDL-C concentrations between the 25th and 50th 
percentile for age and gender.ls Based on tablet counts at 
each visit, there was a 93% compliance rate in both groups. 
two treatment groups (group I = pravastatin with or without other 
lipid-lowering agents, group II = other lipid-lowering agents with- 
out pravastatin). Data from the one premenopausal woman in the 
study was excluded in analyzing female gonadal function. Sample 
sizes were calculated to detect a difference in serum testosterone 
levels of at least 30% between groups at 12 months with a power of 
0.8 and an cx of .05. 
Effects on Adrenal Function 
Data are presented as means ? standard error of the mean. The 
null hypothesis was rejected at a P value of less than .05. Statistical 
tests included paired or unpaired Student’s t test and repeated- 
measures ANOVA. For those variables analyzed by the ANOVA 
model, we assessed the effect of treatment group, month of testing, 
and their interaction. Corticotropin- and HCG-stimulation tests 
were analyzed by evaluating the area under the response curve and 
the peak 6 (maximum serum level minus basal concentration) 
response. Men and women were analyzed separately for serum 
total and free testosterone, estradiol, progesterone, FSH, and LH 
determinations. 
DHEA-S. Mean basal serum DHEA-S levels did not 
change significantly in either group (Table 2). In contrast, 
the DHEA-S response (peak - basal levels) to Cortrosyn 
administration decreased in patients tested at 6 months 
(n = 46; paired Student’s t 
RESULTS 
Baseline 
(aged 52 k 1 
years, women postmenopausal) 
participated in a prospective endocrine evaluation 
Cortisol. basal cortisol levels remained 
(Table 2). 
Similarly, basal corticotropin levels did not 
change. The cortisol response to corticotropin 
months did not change 
ment, the mean concentration 
Table Basal Hormone Concentrations Women in I (pravastatin-treated) Group II (other 
lipid-lowering 0,612, 18, and 24 Months 
Months 
0 6 12 18 24 
I II I II I Ii I II I II 
DHEA-S (pg/dL) 
Mean 101.6 123.1 108.7 121.8 142.3 128.4 101.1 135.6 113.2 66.1 49.9 108.0 89.0 172.0 130.0 
?SEM 12.6 23.1 11.3 13.5 28.6 12.9 13.2 19.6 11.1 23.5 - 42.3 42.0 
Cortisol (pg/dL) 
Mean 14.3 13.0 13.9 13.9 14.1 14.0 12.3 13.6 12.8 13.9 15.6 5.0 12.1 14.5 13.0 
tSEM 0.9 0.8 0.7 0.8 0.7 0.6 0.7 0.9 0.5 1.4 - .9 1.2 
Corticotropin (pg/mL) 
Mean 69.0 49.4 62.6 48.7 42.6 46.8 48.2 35.1 43.6 - - - 80.0 60.0 70.0 
+SEM 7.6 6.9 5.7 4.5 7.1 3.8 4.8 4.1 3.5 _ _ - - - 14.0 
Aldosterone (ng/dL) 
Mean 8.7 7.6 8.3 8.6 7.5 8.2 9.9 11.9 10.6’ 9.1 5.8 7.0 10.1 21.4 16.0 
?SEM .8 1.3 0.7 0.8 1.0 0.6 1.1 2.5 1.1 1.5 - 1.7 - - 6.0 
Renin (ng/mL/h) 
Mean 2.72 3.83 3.07 2.54 2.14 2.39 6.17 3.11 5.40 10.06 6.09 8.2 - - - 
tSEM 0.24 0.61 0.26 0.25 0.37 0.21 3.45 0.88 2.59 2.35 - 2.0 - - - 
N 43 21 64 40 19 59 35 19 54 9 1 10 1 1 2 
NOTE. All data are means 2 SEM. 
*P c .05 for all patients as a whole at 12 months. 
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t 
DHEA-S 
120 159GROUP 1 
men or postmenopausal women (Tables 3 and 4). Only one 
woman was premenopausal, and there were no statistically 
significant changes in her serum levels (data not shown). 
Among the men, 28 subjects (72%) showed a decrease in 
basal total testosterone levels at 12 months regardless of 
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1 
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Fig 2. Maximum delta adrenal steroid response to 250 pg intrave- 
nous Cortrosyn (corticotropin). Peak delta (maximum response minus 
basal concentration) plasma DHEA-S (A), cortisol(B), and aldosterone 
(C) responses were measured after administration of Cortrosyn. 
months was significantly higher (10.6 * 1.5 pg/dL) than 
that observed at baseline (8.3 2 0.7 ug/dL, P < .Ol). How- 
ever, basal concentrations (8.8 2 1.4 ,ug/&., n = 10) re; 
turned to baseline by 18 months (Table 2). Although a 
between-group comparison could not be performed at 18 
months because of a small sample size, the aldosterone 
response to corticotropin administration did not change 
over the l&month period (Fig 2C). 
Eff&s on Gonadal Function 
There were no statistically significant differences in mean 
basal levels of total or free testosterone, FSH, LH, estra- 
dial, or progesterone over a period of 24 months for either 
A subset of 10 men with a mean age (48 t 4 years) 
similar to that of the group as a whole received an HCG 
stimulation test and semen analysis; only data through 12 
months are presented since the sample sizes were small at 
18 and 24 months. Total (Fig 3A) and free testosterone (Fig 
3B) response (peak - basal levels) to the administration of 
HCG did not change with treatment during 24 months of 
follow-up evaluation. A decrease in mean semen volume 
and sperm count was observed at 6 months (P < .05) in all 
men regardless of treatment assignment; values returned 
toward baseline by 12 months. Mean sperm motility de- 
creased in men from both groups at 6 and 12 months 
(P < .OS). No differences were noted in these variables 
between group I and group II (Fig 4). 
DISCUSSION 
We sought to compare the long-term effects of decreas- 
ing LDL-C levels on steroid hormone metabolism using an 
HMG-CoA reductase inhibitor. In our patients studied 
over 2 years, basal cortisol and DHEA-S levels did not 
change with pravastatin use. The increase in basal aldoste- 
rone levels at 12 months (P < .05) was not specific for 
pravastatin, since it was observed in subjects regardless of 
treatment assignment. The secretory reserve of cortisol and 
aldosterone, as determined by a Cortrosyn stimulation test, 
was maintained throughout the study. However, the capac- 
ity-to stimulate DHEA-S secretion in response to corticotro- 
pin decreased in subjects from both groups regardless of 
treatment assignment. Thus this occurred even with choles- 
tyramine, which does not affect de novo synthesis of cho- 
lesterol within the adrenal gland. This finding is difficult to 
interpret and is probably clinically insignifcant, since 
DHEA-S has such a long serum half-life. 
In this study, men and postmenopausal women main- 
tained basal sex hormone secretion throughout the 2 years. 
Possible detrimental effects on premenopausal women 
cannot be excluded from this investigation. Obviously, it 
would be unlikely to detect changes in serum progesterone 
levels, since this hormone is secreted in such low concentra- 
tions in postmenopausal women. Semen analyses obtained 
in a subset of men showed reductions in sperm count, 
motility, and percent normal sperm over the course of 2 
years in men in both groups. There were no dilferenccs 
noted between those men treated with pravastatin versus 
those treated with other lipid-lowering agents. Although 
patients were given strict instructions on how to obtain 
fresh samples, semen analyses can be difficult to interpret, 
especially since there is considerable variation for individ- 
ual semen specimens from the same subject, Sexual func- 
tion was not adequately investigated. 
The lack of effect of pravastatin compared with resin on 
steroid hormone metabolism that we observed in this study 
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Table 3. Gonadal Functions: Basal Serum Hormone Concentrations for Women in Group I (pravastatin-treated) and Group II (other 
lipid-lowering agents) at 0,6, and 12 Months 
Months 
0 6 12 






















15.3 12.0 14.2 19.2 11.2 16.4 18.8 25.4 21.1 
2.0 2.0 2.0 4.0 1.0 3.0 2.0 9.0 4.0 
0.5 0.6 0.5 6.5 0.6 0.5 0.4 0.7 0.6 
0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.4 0.2 
37.3 30.3 34.8 34.9 29.1 32.9 37.7 33.6 36.0 
4.1 3.5 2.9 4.2 2.5 2.9 4.9 4.1 3.3 
34.8 33.4 34.3 37.5 39.7 38.3 35.6 32.5 34.4 
3.3 4.6 2.6 4.3 4.6 3.2 4.7 4.7 3.3 
24.6 30.9 26.9 13.3 16.9 14.5 17.1 20.5 18.4 
10.3 15.5 8.5 2.3 8.1 3.1 6.0 6.1 4.3 
0.19 0.39 0.26 0.19 0.15 0.18 0.17 0.19 0.18 
0.03 0.22 0.08 0.03 0.02 0.02 0.03 0.04 0.02 
16 9 25 15 8 23 12 8 20 
NOTE. All data are means ? SEM 
may be a function of the pravastatin dose or tissue specific- is no evidence for this, perhaps at abnormally low levels of 
ity. It is unlikely that drug dosage would have an effect, serum lipids there may be harmful effects on steroid 
since subjects varied their drug dosages throughout the synthesis. The study subjects were at best brought into the 
study depending on their serum lipid ltvels. Although there normal range. 
Tabfe 4. Gonadal Function. Basal Serum Hormone Concentrations for Men in Group I (pravastatin-treated) and Group II (other lipid-lowering 
agents) at 0,6,12,16, and 24 Months 
Months 
0 6 lz 18 24 
I II Total I II Total I II Total I II Total I II Total 
504.0 518.0 508.0 501.2 511.0 504.0 460.0 431.0 450.0 600.0 570.0 589.0 355.0 290.0 355.0 
26.0 26.0 20.0 36.0 38.0 27.0 66.0 24.0 41.0 121.0 - 10.0 5.0 - 5.0 
17.2 16.0 16.8 16.8 16.6 16.7 15.6 17.1 16.1 16.8 1.7 6.8 13.6 19.2 13.6 






















4.8 4~1 4.6 3.8 3.6 3.8 11.2 4.0 8.8 7.0 4.8 5.9 9.7 8.3 9.0 
0.7 0.4 0.5 0.5 0.4 0.4 6.8 0.6 4.6 0 - 1.4 - - 0.9 
4.5 4.6 4.5 3.2 3.2 3.2 4.1 3.7 4.0 3.9 2.0 2.9 5.1 8.7 6.9 
0.6 0.6 0.4 0.4 0.3 0.3 0.7 0.5 0.5 1.4 - 1.2 - - 1.8 
28.8 26.7 28.2 32.2 26.0 30.3 27.2 22.6 25.6 18.3 8.0 13.1 8.0 14.9 11.5 
3.3 2.9 2.4 2.3 2.6 1.8 2.7 2.5 2.0 10.0 - 6.4 - - 3.5 
0.32 0.32 0.32 0.29 0.27 0.28 0.26 0.29 0.27 0.4 0.3 0.35 0.3 0.1 0.2 
0.04 0.05 0.03 0.03 0.03 0.02 0.02 0.03 0.02 0.1 - 0.06 - - 0.2 
27 12 39 25 11 36 22 11 33 3 1 4 1 1 2 
NOTE. All data are means -c SEM. 
































Fig 3. Maximum delta testosterone response to HCG administra- 
tion. Peak delta (maximum response level minus basal concentration) 
plasma total (A) and free (6) testosterone responses ware measured 
after administration of HCG 2,500 U intramuscularly (n = 10 at 
baseline, n = 5 at 6 months, n = 10 at 12 months). 
Tissue specificity may account for the limited effect of 
pravastatin, since the drug induced less than a 14% inhibi- 
tion of cholesterol synthesis in vivo in mouse adrenal and 
testis as compared with a 90% inhibition noted in the liver 
and ileum.’ In male Wistar rats, pravastatin (CS-514) 
elicited a 7.6% and 7.8% inhibition of sterol synthesis in the 
testis and adrenal gland, respectively.6 Similarly, pravas- 
tatin was unable to enter the intact lens of rats and was 
100-fold less inhibitory of [14C]acetate incorporation into 
cholesterol in the lens compared with lovastatin or simvas- 
tatinz4 
In summary, basal and Cortrosyn-stimulated cortisol and 
aldosterone secretion did not change during treatment with 
pravastatin. The secretory response of DHEA-S to cortico- 
tropin administration was impaired at 6 and 12 months; 
however, this effect was also noted in a control group 
receiving cholestyramine. Testicular function, as evaluated 
by basal and HCG-stimulated testosterone levels, did not 
change. Since the changes recorded were observed in both 
the pravastatin-treated patients and in those treated with 
500- 
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Fig 4. Semen analyses in men during 0, 6, and 12 months of 
lipid-lewering intervention. Data are means + SEM for all men as a 
whole and for the man in group I (pravastatin-treated) or group II 
(other lipid-lowering agents). (A) Sperm counts; (6) percent normal 
sperm; (C) percent motile; ID) semen volume. The number of subjects 
participating from group I and II, respectively, at month 0 was 9 and 5. 
at month 6, 8 and 5, at month 12, 6 and 4. *P < .05 compared with 
baseline. 
other lipid-lowering agents, it is possible that any impair- 
ment in steroid hormone secretion is a function of the 
decrease in lipid levels rather than a specific effect of 
HMG-CoA redactase inhibition. 
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